For Strengthening India’s Pharmaceutical Ecosystem, NIPER-Boehringer MoU for Education and Research & AMRITVA Cohort 2 Unveiled
For Strengthening India’s Pharmaceutical Ecosystem, NIPER-Boehringer MoU for Education and Research & AMRITVA Cohort 2 Unveiled

To advance pharmaceutical education and research in India, a Memorandum of Understanding (MoU) has been signed between National Institute of Pharmaceutical Education and Research (NIPER), Raebareli and Boehringer Ingelheim India Pvt. Ltd. The MoU was signed in the presence of Shri Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers in New Delhi.
On the occasion, Cohort 2 of AMRITVA (Alliance for Medicinal Research, Innovation, Translation & Value Acceleration) to strengthen India’s innovation system and enable translation of research outcomes into viable pharmaceutical products and entrepreneurial ventures was also launched. AMRITVA is implemented by the Startup Incubation and Innovation Centre (SIIC), IIT Kanpur, in partnership with the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli. This is an initiative supported under Corporate Social Responsibility (CSR) by Boehringer Ingelheim India Pvt. Ltd.
In his address, Shri Manoj Joshi underscored the role of collaborative partnerships between academia and industry in strengthening the research-to-market pipeline. He noted that such initiatives are critical for advancing domestic innovation capabilities, encouraging entrepreneurship, and ensuring wider access to cost-effective healthcare solutions.
Shri Awadhesh Kumar Choudhary, Senior Economic Advisor, Department of Pharmaceuticals; Ms. Anugraha P, Director, Department of Pharmaceuticals; and Dr. Ashutosh Agnihotri, Chief Executive Officer of SIIC, IIT Kanpur were present during the event.
As part of Cohort 2, five innovators have been selected for grant support aimed at facilitating the commercialization of their research. Financial assistance of ₹8 lakh each has been provided to three faculty-led projects, while two research scholar-led projects have been awarded ₹6 lakh each.
The MoU signed between Boehringer Ingelheim India and NIPER Raebareli, including its Centre of Excellence for Novel Drug Delivery Systems (CoE-NDDS), establishes a framework to strengthen academic and research collaboration in areas such as pharmaceutical technologies, novel drug delivery systems, academic exchange, and capability-building programmes.
As part of this collaboration, Boehringer Ingelheim will provide access to its opnMe® open science platform to researchers and institutions, enabling scientific exchange and accelerating innovation in healthcare.
The Department of Pharmaceuticals is supporting the country’s pharmaceutical sector to transition from a volume-driven to a value-driven sector with focused policy interventions, infrastructure development, strengthened industry-academia partnerships, and incubation-led commercialization efforts which are aligned with the broader vision of Viksit Bharat 2047.
***
PC/PM